Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Emmaus Life Sciences ( (EMMA) ) has provided an announcement.
On March 2, 2026, Emmaus Life Sciences and South Korea–based NeoImmuneTech entered into an Exclusive Supply Agreement tied to their December 24, 2025 License and Exclusive Distribution Agreement. Under the new supply arrangement, once the license becomes effective, Emmaus will be the exclusive supplier and NeoImmuneTech the exclusive purchaser, subject to limited exceptions, of Endari and any generic equivalents for sickle cell disease in the U.S., its territories and possessions, and Canada, with pricing set at Emmaus’s production cost plus a specified double-digit margin.
The effectiveness of the license, and thus the supply deal, depends on NeoImmuneTech securing necessary regulatory approvals and other conditions, and either party may terminate the license if these conditions are not met by October 1, 2026, unless Emmaus is at fault for the delay. The agreements, if consummated, would shift commercial responsibility for marketing and distribution of Endari in the covered territories to NeoImmuneTech while positioning Emmaus as the dedicated manufacturing and supply partner, potentially reshaping Emmaus’s revenue profile toward margin-based product supply.
The most recent analyst rating on (EMMA) stock is a Hold with a $0.01 price target. To see the full list of analyst forecasts on Emmaus Life Sciences stock, see the EMMA Stock Forecast page.
Spark’s Take on EMMA Stock
According to Spark, TipRanks’ AI Analyst, EMMA is a Neutral.
The score is primarily constrained by weak financial performance (declining revenue, ongoing losses, negative cash flow, and a stressed balance sheet with negative equity). Technicals are mixed with weak momentum and MACD negative, and valuation is limited by loss-making status and no dividend. A positive offset is the Endari distribution/licensing agreement, though it carries execution and conditionality risk.
To see Spark’s full report on EMMA stock, click here.
More about Emmaus Life Sciences
Emmaus Life Sciences, Inc. is a biopharmaceutical company focused on treatments for sickle cell disease. Its primary commercial product is Endari, a prescription-grade L-glutamine oral powder, and the company targets patients with sickle cell disease in the U.S., its territories and possessions, and Canada through specialized licensing and distribution arrangements.
Average Trading Volume: 57,293
Technical Sentiment Signal: Strong Sell
Current Market Cap: $926.1K
For an in-depth examination of EMMA stock, go to TipRanks’ Overview page.